ArrowMark Colorado Holdings LLC Has $9.94 Million Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

ArrowMark Colorado Holdings LLC raised its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 442.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 389,448 shares of the biopharmaceutical company's stock after acquiring an additional 317,698 shares during the quarter. ArrowMark Colorado Holdings LLC owned approximately 0.07% of Royalty Pharma worth $9,935,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AXA S.A. raised its holdings in shares of Royalty Pharma by 761.9% during the 4th quarter. AXA S.A. now owns 156,131 shares of the biopharmaceutical company's stock worth $3,983,000 after acquiring an additional 138,017 shares during the period. AlTi Global Inc. purchased a new stake in shares of Royalty Pharma during the fourth quarter worth $9,887,000. Caisse DE Depot ET Placement DU Quebec acquired a new position in shares of Royalty Pharma during the fourth quarter worth about $18,183,000. Regal Partners Ltd increased its position in shares of Royalty Pharma by 21.9% in the 4th quarter. Regal Partners Ltd now owns 1,435,956 shares of the biopharmaceutical company's stock valued at $36,631,000 after purchasing an additional 258,355 shares during the last quarter. Finally, PDT Partners LLC raised its stake in Royalty Pharma by 124.8% in the fourth quarter. PDT Partners LLC now owns 69,533 shares of the biopharmaceutical company's stock valued at $1,774,000 after buying an additional 38,599 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Wall Street Analyst Weigh In

Separately, Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Royalty Pharma has an average rating of "Buy" and a consensus target price of $42.50.

Royalty Pharma Stock Performance

Shares of RPRX stock traded up $0.65 on Wednesday, hitting $32.76. 6,085,887 shares of the stock traded hands, compared to its average volume of 3,283,447. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company's fifty day moving average is $32.42 and its 200 day moving average is $29.67. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The company has a market capitalization of $18.88 billion, a PE ratio of 22.59, a PEG ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a dividend of $0.22 per share. The ex-dividend date is Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.69%. Royalty Pharma's dividend payout ratio (DPR) is presently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.